Compare Illumina, Inc. (ILMN) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Wendys Co — how do they compare? Illumina, Inc. trades at $265.01 (market cap $39.95B), while Wendys Co trades at $6.21 (market cap $1.19B). The key difference: Illumina, Inc. is far larger — about 33.6× Wendys Co's market cap, and Wendys Co pays a 4.49% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Wendys Co for 77 Days on average.
| ILMN | WEN | |
|---|---|---|
Market Cap | $39.95B | $1.19B |
Volume | 3,169,503 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $293.69 | $9.33 |
52-Week Low | $91.00 | $6.10 |
Typical Hold Time | 83 Days | 77 Days |
Enterprise Value | $41.31B | $4.92B |
Dividend Yield | — | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Wendy's stock (WEN) trades at $6.11, down 0.81% on the day, reflecting ongoing pressure from declining sales and a major franchisee bankruptcy. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal a low P/E of 9.45 and strong ROE of 108.04%, but net income margins have fallen to 5.72%. Recent news highlights competitive struggles and store closures, though the company continues to beat earnings expectations.
The outlook remains cautious due to operational headwinds and high debt, but the current valuation may appeal to value investors. Risks include franchisee instability and intense competition. Analyst consensus is mixed with a $7.58 price target, suggesting limited upside from current levels amid uncertain recovery prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
